BBB National Programs’ National Advertising Division (NAD) plans to refer Kendal Nutricare Limited to government and state agencies, as well as relevant advertising platforms, following the company’s decision not to participate in a compliance inquiry involving its Kendamil infant formula advertising.
The referral follows concerns raised by Abbott Laboratories regarding advertising claims previously examined in NAD Case #7562. The original proceeding addressed representations involving whole milk, breast milk, human milk oligosaccharides (HMOs), milk fat content, and Kendamil’s brand heritage.
According to BBB National Programs, NAD had recommended that Kendal discontinue or modify certain advertising claims. Kendal initially agreed to follow those recommendations and voluntarily discontinued an additional claim concerning its use of whole milk. However, Abbott subsequently contacted NAD with concerns about nearly all the claims covered by the original decision.
Kendal informed NAD that it would not participate in the subsequent compliance inquiry. Consequently, NAD will refer the matter under its NAD/NARB Procedures to appropriate enforcement authorities and advertising platforms with which it maintains reporting relationships.
The development highlights the role of independent advertising self-regulation in monitoring claims after an initial review and the potential consequences when advertisers decline to participate in compliance proceedings.
Advertising Compliance Moves Beyond Initial Claim Reviews
NAD operates as part of BBB National Programs’ advertising self-regulatory framework, reviewing national advertising claims and assessing whether they are adequately supported. Its decisions and recommendations are intended to encourage truthful and substantiated advertising practices.
The Kendamil matter illustrates that an advertiser’s initial agreement to modify or discontinue claims does not necessarily end scrutiny. Subsequent concerns from competitors can lead to further compliance reviews, particularly when questions arise about whether earlier recommendations have been implemented.
In this case, Abbott’s challenge focused on claims previously addressed in the original proceeding. The decision not to participate in the compliance inquiry prompted NAD to pursue referrals rather than conclude the review through the advertiser’s participation.
The referral itself should not be interpreted as a final government finding of wrongdoing or an independent determination that every challenged claim is misleading. It places the matter before relevant agencies and platforms for their own review and possible action.
Market Landscape: Advertising Verification and Platform Accountability
The case has implications for advertisers operating in highly regulated consumer categories, including infant nutrition, healthcare, and food products. Claims concerning nutritional composition, ingredient comparisons, and similarities to breast milk can require particularly careful substantiation.
For advertising platforms, the referral underscores the importance of compliance processes that extend beyond campaign approval. Platforms may face requests to review advertising when claims are questioned through established industry self-regulatory channels.
Advertisers and agencies must also consider the potential reputational and operational consequences of unresolved advertising challenges. Claim substantiation, documentation, consistent messaging, and timely responses to compliance inquiries are important components of campaign governance.
From an AdTech perspective, the development is relevant to advertising verification and platform accountability, although the announcement does not identify specific platforms, automated detection technologies, ad-serving systems, or measurement products involved in the matter.
Strategic Outlook: Greater Importance of Advertising Governance
The referral reinforces the relationship between advertising self-regulation, competitor challenges, government oversight, and digital platform enforcement.
For brands, the commercial risk extends beyond the original advertising claim. Failure to engage with compliance inquiries can result in additional scrutiny from external authorities and platforms, potentially affecting advertising distribution and campaign continuity.
Agencies and media partners may also need stronger internal review procedures for claims involving sensitive product categories. This includes maintaining evidence supporting product comparisons, nutritional representations, and heritage-related messaging before campaigns reach consumers.
For the wider advertising ecosystem, the case demonstrates why transparent claim verification and responsive compliance processes remain important as brands distribute campaigns across multiple digital channels.
NAD’s referral represents a procedural escalation, not a final enforcement ruling. The next developments will depend on the responses of the relevant agencies and advertising platforms.
Top Insights
- Compliance escalation: NAD plans to refer Kendal Nutricare following its decision not to participate in the compliance inquiry.
- Competitor challenge: Abbott raised concerns about claims previously examined in Case #7562.
- Advertising substantiation: Claims involving nutritional composition and breast milk comparisons remain central to the dispute.
- Platform accountability: Advertising platforms with NAD reporting relationships may receive the referral for review.
- No final enforcement finding: The referral does not itself establish a government violation or final determination of misleading advertising.
Get in touch with our Adtech experts
